Company / Operating Income
Viridian Therapeutics, Inc.\DE Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$363.4M
FY2025
5-year range
-$363.4M / -$79.7M
FY2021-FY2025
Trend
-21.5%
vs FY2024
Sector context
#172 of 204
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's operating income of -$363M is lower than 84% of companies in the Health Care sector (FY2025). Operating Income has declined for 4 consecutive years, from -$80M in FY2021 to -$363M in FY2025.
Based on SEC 10-K filings.
-$363M in FY2025.
Declined from -$254M to -$363M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 204This company -$363.4M Sector average $107.7M
▼
-437.4% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's operating income has declined for 4 consecutive years.
- In FY2025, operating income decreased 21.5% year-over-year.
- Ranks #172 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$363.4M | -21.5% |
| FY2024 | -$299.0M | -17.5% |
| FY2023 | -$254.4M | -89.5% |
| FY2022 | -$134.3M | -68.5% |
| FY2021 | -$79.7M | +27.8% |
| FY2020 | -$110.4M | -162.9% |
| FY2019 | -$42.0M | -26.9% |
| FY2018 | -$33.1M | -24.7% |
| FY2017 | -$26.5M | -56.2% |
| FY2016 | -$17.0M | -51.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026